PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Evolve: specialist pharmaceutical and biotechnology IP firm

Our offering

Evolve is a specialist pharmaceutical and biotechnology IP firm. Our patent directors have run IP in-house, and we provide IP strategy, drafting and prosecution, freedom to operate, oppositions, due diligence and deals worldwide, with a global strategic approach.

We work with start-ups, biotech companies, established pharma, investors, universities, CROs and CMOs and international IP counsel.

  • Evolve AI
  • Fractional IP counsel
  • Technologies
Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

IP Stars from Managing IP logo

The team are thoughtful and intuitive and provide a personable service.

IP Stars from Managing IP logo

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

IP Stars from Managing IP logo

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

IAM Patent 1000 logo

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

IAM Patent 1000 logo

Evolve Intellectual Property is a growing firm, with an excellent reputation.

IAM Patent 1000 logo

Evolve is a refreshing change to the traditional patent attorney firm approach – much more nimble and responsive.

IAM Patent 1000 logo

Fractional IP counsel

Do you need experienced IP leadership without the overhead of a full-time in-house team? Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP. Our patent directors have run IP inside pharma and biotech companies, so they bring the real-world industry experience that you only get working in-house, backed by a specialist team and our own AI tools, with a global strategic approach.

Find out more
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Evolve AI

We are pharma patent attorneys who build and use our own AI agents. Albert for validity and competitive intelligence, Popper for global prosecution, Darwin for drafting, Cassandra for due diligence, Gilbert for quality and Franklin for invention spotting do the groundwork, so we can look at more, in more depth and earlier, while our attorneys make every judgement call.

Find out more
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

Technologies

We are technology specialists. Our team’s scientific and in-house experience spans pharmaceuticals, antibodies and other biologics, cell and gene therapies and AI drug discovery, so we understand the science behind your IP as well as the law.

Find out more
  • Pharmaceuticals
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • All technologies

Insights

Visit Evolve Insights for our latest articles and webinars on key emerging trends and strategic considerations in pharmaceutical IP.

Read more
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Any inhibitor will do: Functional claims need not be limited by modality (T 1355/24)

  • 5th November 2026
How much data does a Patentee need to claim every molecule that hits a target? For antibodies, the Boards of Appeal have long accepted that identifying a new target or epitope can justify a claim to the whole functional genus of antibodies that bind it. The recent decision in T 1355/24 extends that generosity to…
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

AI in the patent industry: Instant coffee Copilot

  • 4th November 2026
It is now abundantly clear that AI cannot be ignored by the patent industry. However, amongst the private practice firms, there still remains a divergence of approach, with many attorneys still not using AI in their day-to-day practice.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Prophetic prior art and the common light chain mouse (T 0527/24)

  • 1st November 2026
Kymab is famous as the Cambridge antibody mouse company that fought Regeneron all the way to the UK Supreme Court, and won, on sufficiency (no mean feat, given the very strict approach the UK courts have taken to the sufficiency test for pharmaceutical inventions in recent years). In T 0527/24, Kymab was on the other…
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: The sneaky practice of prompt injection (and what to do about it)

  • 30th October 2026
As patent attorneys, we are by now all hopefully well versed in the confidentiality and hallucination risks of using AI. However, as AI tools are increasingly used to read, summarise and come to conclusions about third-party documents, there is another risk we need to think about: prompt injection. This is the sneaky practice of hiding…

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalised approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Subscribe
  • Contact us
  • Cookie Notice